6-MeO-DMT

6-MeO-DMT (6-methoxy-N,N-dimethyltryptamine; CAS 2426-88-2) is a substituted indoleethylamine of the tryptamine structural class, defined by the placement of a methoxy substituent at the 6-position of the indole ring rather than at the 5-position occupied in its well-characterized positional isomer 5-MeO-DMT. The compound was first described in the scientific literature by 1968 and was assessed in structure-activity relationship studies of serotonergic tryptamines during the 1970s and 1980s. Despite acting as an agonist at the serotonin 5-HT2A receptor and as a non-selective agonist at multiple additional serotonin receptor subtypes, 6-MeO-DMT displays markedly reduced receptor affinity relative to both DMT and 5-MeO-DMT: its 5-HT2A binding affinity is 12- to 43-fold lower than that of 5-MeO-DMT and approximately 6-fold lower than that of DMT, while its 5-HT1A affinity is approximately 110-fold lower than that of 5-MeO-DMT. These attenuated binding properties correlate with the absence of the head-twitch response in rodent models, failure to substitute for the classical hallucinogen DOM in drug discrimination paradigms, and overall lack of psychedelic-like behavioral effects in all animal assays conducted to date.

The pharmacological profile of 6-MeO-DMT is of contemporary research interest for two principal reasons. First, the compound exemplifies how a single-atom positional shift of the methoxy group on the indole ring (from position 5 to position 6) produces a qualitative transition from hallucinogenic to non-hallucinogenic pharmacology while preserving the fundamental tryptamine scaffold and serotonin receptor agonist mechanism, providing a critical negative-control and structure-activity reference point for the investigation of 5-HT2A-mediated psychedelia. Second, the compound belongs to a growing class of non-hallucinogenic serotonin 5-HT2A receptor agonists (alongside tabernanthalog, 6-fluoro-DET, 2-bromo-LSD, lisuride, and others) that retain the capacity to promote neuroplasticity through 5-HT2A-dependent signaling without producing the subjective and behavioral effects associated with classical psychedelics, positioning it as a candidate scaffold for psychoplastogenic drug development.

6-MeO-DMT has not been tested in humans. No human pharmacokinetic, pharmacodynamic, or clinical efficacy data exist. The compound is presumed to undergo oxidative deamination by monoamine oxidase A (MAO-A) consistent with the metabolic fate of structurally related N,N-dimethylated tryptamines, with potential minor O-demethylation pathways contributing to total clearance. The compound is not an explicitly controlled substance in the United States, though it may be considered a Schedule I controlled substance as a positional isomer of 5-MeO-DMT under the Federal Analogue Act. This monograph reviews the chemistry, synthesis, and structural classification of 6-MeO-DMT; the receptor pharmacology and structure-activity relationships within the methoxytryptamine series; the extrapolated pharmacokinetic profile; the preclinical pharmacology evidence base; the absence of clinical data; sourcing and quality verification considerations; reconstitution and handling; stack interactions and combinations; adverse-event and safety signal assessment; and a comparative evaluation of five structurally or mechanistically related tryptamine compounds against 6-MeO-DMT on five assessment standards.